FR2706772B1 - - Google Patents

Info

Publication number
FR2706772B1
FR2706772B1 FR9307559A FR9307559A FR2706772B1 FR 2706772 B1 FR2706772 B1 FR 2706772B1 FR 9307559 A FR9307559 A FR 9307559A FR 9307559 A FR9307559 A FR 9307559A FR 2706772 B1 FR2706772 B1 FR 2706772B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9307559A
Other languages
French (fr)
Other versions
FR2706772A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacsyn SA
Original Assignee
Vacsyn SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vacsyn SA filed Critical Vacsyn SA
Priority to FR9307559A priority Critical patent/FR2706772A1/fr
Publication of FR2706772A1 publication Critical patent/FR2706772A1/fr
Application granted granted Critical
Publication of FR2706772B1 publication Critical patent/FR2706772B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9307559A 1993-06-22 1993-06-22 Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. Granted FR2706772A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9307559A FR2706772A1 (en) 1993-06-22 1993-06-22 Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9307559A FR2706772A1 (en) 1993-06-22 1993-06-22 Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.

Publications (2)

Publication Number Publication Date
FR2706772A1 FR2706772A1 (en) 1994-12-30
FR2706772B1 true FR2706772B1 (me) 1995-09-01

Family

ID=9448412

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9307559A Granted FR2706772A1 (en) 1993-06-22 1993-06-22 Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.

Country Status (1)

Country Link
FR (1) FR2706772A1 (me)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662776B2 (en) 2005-07-05 2010-02-16 Biotempt B.V. Treatment of tumors using short peptides from human chorionic gonadotropin (HCG)
US7795226B2 (en) 2006-03-07 2010-09-14 Biotempt B.V. Control of radiation injury
US7820617B2 (en) 1998-05-20 2010-10-26 Biotempt B.V. Methods of selecting immunoregulator peptides obtained from gonadotropins
US7928074B2 (en) 2002-12-30 2011-04-19 Amgen Inc. Combination therapy with co-stimulatory factors
USRE43309E1 (en) 2000-03-29 2012-04-10 Biotempt B.V. Immunoregulatory compositions

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
FI104363B (fi) * 1997-05-19 2000-01-14 Timo Kalevi Korpela Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
FR2674433A1 (fr) * 1991-03-27 1992-10-02 Pasteur Institut Medicament contenant un agent inhibant in vivo l'apoptose pathologique et applications.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820617B2 (en) 1998-05-20 2010-10-26 Biotempt B.V. Methods of selecting immunoregulator peptides obtained from gonadotropins
USRE43309E1 (en) 2000-03-29 2012-04-10 Biotempt B.V. Immunoregulatory compositions
US7928074B2 (en) 2002-12-30 2011-04-19 Amgen Inc. Combination therapy with co-stimulatory factors
US7662776B2 (en) 2005-07-05 2010-02-16 Biotempt B.V. Treatment of tumors using short peptides from human chorionic gonadotropin (HCG)
US7795226B2 (en) 2006-03-07 2010-09-14 Biotempt B.V. Control of radiation injury

Also Published As

Publication number Publication date
FR2706772A1 (en) 1994-12-30

Similar Documents

Publication Publication Date Title
FR2707013B1 (me)
FR10C0012I2 (me)
FR2706747B1 (me)
FR2701905B1 (me)
FR2709800B1 (me)
EP0702629A4 (me)
DK0611885T3 (me)
DK22893A (me)
FR2706732B1 (me)
IN187833B (me)
FR2706742B1 (me)
FR2707016B1 (me)
ECSDI930108S (me)
IN178723B (me)
IN175598B (me)
IN175919B (me)
IN176387B (me)
IN176915B (me)
IN177161B (me)
IN177607B (me)
IN177688B (me)
IN178212B (me)
IN178359B (me)
IN186397B (me)
IN186417B (me)

Legal Events

Date Code Title Description
ST Notification of lapse
ST Notification of lapse